Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Royale Energy, Inc. Reports Positive Cash Flow From Operations for 2012 to Royce Focus Trust (NASDAQ: FUND) as of January 31, 2013

This site contains about 74,006 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   800   900   1,000   1,100   1,200   1,300   1,400   1,500   1,600   1,750   1,760   1,770   1,780   1,790   1,800   1,810   1,820   1,830   1,843   1,844   1,845   1,846   1,847   1,848   1,849   1,850   1,851   1,852   1,853   1,854   1,855   1,856   1,857   1,858   1,859   1,860   1,861   1,862   1,863   1,864   1,865   1,866   1,867   1,868   1,869   1,870   1,871   1,872   1,880   1,890   1,900   1,910   1,920   1,930   1,940   1,950   2,000   2,100   2,200   2,300   2,400   2,467 

2013/4/16
Royale Energy, Inc. Reports Positive Cash Flow From Operations for 2012
SAN DIEGO, April 16, 2013 (GLOBE NEWSWIRE) -- Royale Energy, Inc. (Nasdaq:ROYL) announced the filing of its annual financial statements for year-end 2012.
View more Royale Energy, Inc. Reports Positive Cash Flow From Operations for 2012 analysis
Sign-up for Royale Energy, Inc. Reports Positive Cash Flow From Operations for 2012 investment picks
2013/5/28
Royale Signs Definitive Agreement to Fund Commencement of Work in Alaska
SAN DIEGO, May 28, 2013 (GLOBE NEWSWIRE) -- Royale Energy, Inc. (Nasdaq:ROYL) today announced that it has completed an agreement with Rampart Energy Ltd of Australia (ASX:RTD) for the development of a portion of Royale's Alaska North Slope property.
View more Royale Signs Definitive Agreement to Fund Commencement of Work in Alaska analysis
Sign-up for Royale Signs Definitive Agreement to Fund Commencement of Work in Alaska investment picks
2013/5/16
Royale's First Quarter Cash Flow From Operations 77% Above Full Year 2012
SAN DIEGO, May 16, 2013 (GLOBE NEWSWIRE) -- Royale Energy, Inc. (Nasdaq:ROYL) today announced financial results for the first quarter of 2013, highlighting increased Cash Flow from Operations.
View more Royale's First Quarter Cash Flow From Operations 77% Above Full Year 2012 analysis
Sign-up for Royale's First Quarter Cash Flow From Operations 77% Above Full Year 2012 investment picks
2013/6/11
Royalty Pharma Acceptances Announcement
NEW YORK , June 11, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels of its Further Increased Offer for Elan Corporation, plc (NYSE: ELN) .
View more Royalty Pharma Acceptances Announcement analysis
Sign-up for Royalty Pharma Acceptances Announcement investment picks
2013/6/7
Royalty Pharma Acceptances Announcement
NEW YORK , June 7, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels of its Increased Offer for Elan Corporation (NYSE: ELN) .
View more Royalty Pharma Acceptances Announcement analysis
Sign-up for Royalty Pharma Acceptances Announcement investment picks
2013/6/6
Royalty Pharma Announces Extension of its Increased Offer
NEW YORK , June 6, 2013 /PRNewswire/ -- Royalty Pharma today announces that the closing date for its Increased Offer made for Elan Corporation, plc (NYSE: ELN) on 23 May 2013 is being extended until 1:00 p.m. (Irish time) / 8:00 a.m. ( New York City time) on Friday, 21 June 2013 and will remain open for acceptance until that time (unless further extended). Capitalised terms used but not defined in this announcement shall have the meaning given to them in Royalty Pharma's Revised Offer Document dated 23 May 2013 .
View more Royalty Pharma Announces Extension of its Increased Offer analysis
Sign-up for Royalty Pharma Announces Extension of its Increased Offer investment picks
2013/4/15
Royalty Pharma Announces Firm Offer to Acquire Elan
Firm, Fully Financed Offer, Made Under Rule 2.5 of the Irish Takeover Rules, Valued at up to US$12 per Elan Share, a 23 Percent Increase Over the Enterprise Value of Royalty Pharma's Initial Proposal Offer Represents a 39 Percent Premium Over of the Undisturbed Elan Enterprise Value NEW YORK , April 15, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), the terms of a firm, all cash offer (the "Offer") for the entire issued and to be issued share capital of Elan Corporation, plc ("Elan") (NYSE: ELN) .
View more Royalty Pharma Announces Firm Offer to Acquire Elan analysis
Sign-up for Royalty Pharma Announces Firm Offer to Acquire Elan investment picks
2013/2/25
Royalty Pharma Announces Proposal To Acquire Elan
Announcement Made Under Rule 2.4 of Irish Takeover Rules NEW YORK , Feb.
View more Royalty Pharma Announces Proposal To Acquire Elan analysis
Sign-up for Royalty Pharma Announces Proposal To Acquire Elan investment picks
2013/5/24
Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
NEW YORK , May 24, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the United States Exchange Act, Echo Pharma Acquisition Limited (" Royalty Pharma ") today announced acceptance levels its original offer for Elan Corporation (NYSE: ELN) .
View more Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements analysis
Sign-up for Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements investment picks
2013/6/11
Royalty Pharma Files Judicial Review Proceedings
NEW YORK , June 11, 2013 /PRNewswire/ -- Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel requiring it to lapse its Further Increased Offer in the event that the ELND005 Transaction and / or the Share Repurchase Program are approved at the Elan (NYSE: ELN) EGM on 17 June 2013 .
View more Royalty Pharma Files Judicial Review Proceedings analysis
Sign-up for Royalty Pharma Files Judicial Review Proceedings investment picks
2013/5/20
Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
Fully Financed, All-Cash Confirmed Offer is Not Conditional on Due Diligence Offer Now Equivalent to a $4.6 Billion Value for Elan's Tysabri Royalty, a 42% Premium to the $3.25 Billion for Which Elan Sold Approximately Half its Interest in Tysabri to Biogen Royalty Pharma Believes Elan Board Failed Stockholders in the Theravance Transaction by Substantially Overpaying and Failing to Negotiate a "Fiduciary Out" NEW YORK , May 20, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to increase its offer for Elan Corporation, plc (NYSE: ELN) to $12.50 per share in cash.
View more Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash analysis
Sign-up for Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash investment picks
2013/6/7
Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
CVR Allows Shareholders to Participate in Tysabri Royalty Upside for all Indications and Cash Flows, Pre- and Post-Patent Expiration Offer Represents Premium of 56% to 97% to Elan's Undisturbed Enterprise Value Royalty Pharma's Offer Will Lapse if Shareholders Approve Any Resolutions at Elan's Extraordinary General Meeting NEW YORK , June 7, 2013 /PRNewswire/ -- Royalty Pharma today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to further increase its offer for Elan Corporation, plc (NYSE: ELN) to $13.00 per share in cash plus a contingent value right ("CVR") worth up to $2.50 per share.
View more Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share analysis
Sign-up for Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share investment picks
2013/5/28
Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
Underscores Compelling Logic for Elan Stockholders to SELL their shares to Royalty Pharma Urges Elan Stockholders to Vote AGAINST Elan Proposed Transactions So As Not to Risk Losing the Royalty Pharma Deal Altogether Minimum Acceptance Threshold of 50% Plus One Share Offer Affords Elan Stockholders the Ability to Speak Their Voice and Avoid Value Destruction NEW YORK , May 28, 2013 /PRNewswire/ -- Royalty Pharma announces today that it has issued an investor presentation related to Royalty Pharma's increased offer to acquire Elan Corporation, plc (NYSE: ELN) for $12.50 per share in cash.
View more Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash analysis
Sign-up for Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash investment picks
2013/5/23
Royalty Pharma Lowers Acceptance Threshold For Elan Offer
LONDON --
View more Royalty Pharma Lowers Acceptance Threshold For Elan Offer analysis
Sign-up for Royalty Pharma Lowers Acceptance Threshold For Elan Offer investment picks
2013/4/15
Royalty Pharma Offers More for Elan
LONDON --U.S.-based pharmaceutical investment firm Royalty Pharma Monday raised its offer for Dublin drug maker Elan Corp.
View more Royalty Pharma Offers More for Elan analysis
Sign-up for Royalty Pharma Offers More for Elan investment picks
2013/6/10
Royalty Pharma Posts Further Revised Offer Document In Offer For Elan Corporation, Plc ("Elan")
NEW YORK , June 10, 2013 /PRNewswire/ -- Following its announcement on 7 June 2013 , Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued a further revised offer document dated 10 June 2013 (the "Further Revised Offer Document"). In the Further Revised Offer Document, Royalty Pharma confirms the Offer Price for Elan Corporation, plc (NYSE: ELN) set forth in its Rule 2.5 Announcement of 7 June 2013 (please see the Further Revised Offer Document for details). The Offer Price comprises $13.00 per share in cash plus a contingent value right ("CVR") worth up to $2.50 per share upon the achievement of certain CVR Payment Events.
View more Royalty Pharma Posts Further Revised Offer Document In Offer For Elan Corporation, Plc ("Elan") analysis
Sign-up for Royalty Pharma Posts Further Revised Offer Document In Offer For Elan Corporation, Plc ("Elan") investment picks
2013/6/10
Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
Urges Shareholders to Vote AGAINST ALL PROPOSALS at Upcoming Elan EGM Royalty Pharma Offers Compelling Immediate Value with Continued Upside participation Voting Deadline for ADS Beneficial Holders in Street Name is this Wednesday at 11:59 p.m. ET NEW YORK , June 10, 2013 /PRNewswire/ -- Royalty Pharma today posted a new investor presentation summarizing its Further Increased Offer for Elan Corporation, plc (NYSE: ELN) and urging Elan shareholders to VOTE AGAINST ALL FOUR of Elan's proposals at its upcoming Extraordinary General Meeting on June 17, 2013 .
View more Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan analysis
Sign-up for Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan investment picks
2013/6/7
Royalty Pharma Raises Elan Offer to $8 Billion
LONDON --U.S. pharmaceutical investor Royalty Pharma AG (RYP.XX) Friday raised its offer for Elan Corp.
View more Royalty Pharma Raises Elan Offer to $8 Billion analysis
Sign-up for Royalty Pharma Raises Elan Offer to $8 Billion investment picks
2013/5/20
Royalty Pharma Raises Takeover Bid for Elan
LONDON --U.S. pharmaceutical investor Royalty Pharma on Monday raised its multibillion-dollar takeover bid for Dublin - based Elan Corp.
View more Royalty Pharma Raises Takeover Bid for Elan analysis
Sign-up for Royalty Pharma Raises Takeover Bid for Elan investment picks
2013/5/29
Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
Elan's proposed transactions offer no coherent strategy and are not in the best interests of Elan or its shareholders Royalty Pharma's offer will lapse if either the Theravance Transaction or the AOP acquisition is approved NEW YORK , May 29, 2013 /PRNewswire/ -- Royalty Pharma announces its recommendation that the shareholders of Elan Corporation, plc (NYSE: ELN) vote "NO" on each of the four proposals offered by Elan at its upcoming extraordinary general meeting on June 17 , 2013.
View more Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting analysis
Sign-up for Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting investment picks
2013/5/23
Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
NEW YORK , May 23, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that it has committed to waive down the Acceptance Threshold from 90 percent to 50 percent of Maximum Elan Shares Affected plus one Elan Share in accordance with the terms of the Revised Offer Document issued today, subject to the conditions summarized below.
View more Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share analysis
Sign-up for Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share investment picks
2013/5/31
Royalty Pharma Responds To Elan's Tysabri Valuation
NEW YORK , May 31, 2013 /PRNewswire/ -- Royalty Pharma is today issuing a presentation outlining why it believes Elan's (NYSE: ELN) valuation of Tysabri, as set out in materials released by Elan on 29 May 2013 , is far too high.
View more Royalty Pharma Responds To Elan's Tysabri Valuation analysis
Sign-up for Royalty Pharma Responds To Elan's Tysabri Valuation investment picks
2013/5/30
Royalty Pharma Response To Elan's "Categorical View On Value"
NEW YORK , May 30, 2013 /PRNewswire/ -- Commenting on Elan's (NYSE: ELN) announcement of last night, Pablo Legorreta , Chief Executive Officer of Royalty Pharma, said: "In its announcement, Elan's Board makes the unrealistic claim that the Tysabri royalty it owns is worth between $6.1 billion and $6.6 billion *.  Elan shareholders should ask themselves, if this is true, why did Elan sell approximately half of the Tysabri economics that it owned to Biogen in February 2013 for $3.25 billion , 29% less than the $4.6 billion value implied by Royalty Pharma's offer, and 46% to 51% less than what the Elan Board is now claiming the other half is worth?
View more Royalty Pharma Response To Elan's "Categorical View On Value" analysis
Sign-up for Royalty Pharma Response To Elan's "Categorical View On Value" investment picks
2013/3/6
Royalty Pharma Statement Regarding Elan Proposal
This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules NEW YORK , March 6, 2013 /PRNewswire/ -- RP Management, LLC ("Royalty Pharma") remains committed to acquiring Elan (NYSE: ELN) on the terms set out in the Proposal Announcement of February 25, 2013 , but continues to be disappointed that the Board of Elan has not engaged in discussions.
View more Royalty Pharma Statement Regarding Elan Proposal analysis
Sign-up for Royalty Pharma Statement Regarding Elan Proposal investment picks
2013/5/2
Royalty Pharma Submits Formal Cash Offer For Elan Corporation, plc ("Elan")
Offer Price Reflects $1 Billion Dutch AuctionStrikePrice of $11.25 per Elan Share NEW YORK , May 2, 2013 /PRNewswire/ -- Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued an offer document dated 2 May 2013 (the "Offer Document").  In the Offer Document, Royalty Pharma confirms the Offer Price set forth in its Rule 2.5 Announcement of 15 April (please see the Offer Document for details). The Offer Price reflects Elan's (NYSE: ELN) $1 billion Dutch Auction share repurchase (the "Dutch Auction") clearing price of $11.25 per Elan Share, the lowest possible price in the range set by the Elan Board.
View more Royalty Pharma Submits Formal Cash Offer For Elan Corporation, plc ("Elan") analysis
Sign-up for Royalty Pharma Submits Formal Cash Offer For Elan Corporation, plc ("Elan") investment picks
2013/6/10
Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
ADS Shareholders Have Only Three Days to Vote ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions* Royalty Pharma Will Lapse its Offer if the Resolutions Are Approved [1],[2] NEW YORK , June 10, 2013 /PRNewswire/ -- Royalty Pharma today urged Elan Corporation, plc (NYSE: ELN) Shareholders to immediately vote AGAINST ALL FOUR resolutions Elan's Board has put forth for the Extraordinary General Meeting ("Elan EGM") on June 17.
View more Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today analysis
Sign-up for Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today investment picks
2013/4/16
Royanne Doi Named Corporate Chief Ethics Officer at Prudential
Prudential Financial, Inc. (NYSE: PRU) announced today that Royanne Doi, chief legal officer at Prudential of Japan (POJ), has been named Prudential's corporate chief ethics officer.
View more Royanne Doi Named Corporate Chief Ethics Officer at Prudential analysis
Sign-up for Royanne Doi Named Corporate Chief Ethics Officer at Prudential investment picks
2013/5/21
Royce Focus Trust (NASDAQ: FUND) as of April 30, 2013
Royce Focus Trust (NASDAQ: FUND) : Closing Prices – April 30, 2013 *The Funds’ P/E ratio calculations exclude companies with zero or negative earnings.
View more Royce Focus Trust (NASDAQ: FUND) as of April 30, 2013 analysis
Sign-up for Royce Focus Trust (NASDAQ: FUND) as of April 30, 2013 investment picks
2013/3/12
Royce Focus Trust (NASDAQ: FUND) as of February 28, 2013
Royce Focus Trust (NASDAQ: FUND) : Closing Prices – February 28, 2013 NAV $7.66 MKT $6.94 Total Return Performance     Periods ended February 28, 2013 NAV MKT   1 Month* -2.42% -2.12% Year to Date* 0.00 5.15 One-Year -2.14 1.48 Three-Year Average Annual 7.14 8.60 Five-Year Average Annual 1.87 0.11 Ten-Year
View more Royce Focus Trust (NASDAQ: FUND) as of February 28, 2013 analysis
Sign-up for Royce Focus Trust (NASDAQ: FUND) as of February 28, 2013 investment picks
2013/2/19
Royce Focus Trust (NASDAQ: FUND) as of January 31, 2013
Royce Focus Trust (NASDAQ: FUND) :   Closing Prices – January 31, 2013 Recent Developments Royce Focus Trust, Inc. is a closed-end diversified management investment company whose shares of Common Stock are listed and traded on the Nasdaq National Market (Nasdaq - FUND). The Fund's investment goal is long-term capital growth, which it seeks by normally investing at least 65% of its assets in equity securities.
View more Royce Focus Trust (NASDAQ: FUND) as of January 31, 2013 analysis
Sign-up for Royce Focus Trust (NASDAQ: FUND) as of January 31, 2013 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Royale Energy, Inc. Reports Positive Cash Flow From Operations for 2012 to Royce Focus Trust (NASDAQ: FUND) as of January 31, 2013
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.